NewsRoom

Archives: Search / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015

2014201320122011201020092008

May 6, 2021
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
Apr 10, 2021
Data Featured in Poster at American Association for Cancer Research Annual Meeting 2021
Feb 4, 2021
--Multiple Clinical Development Milestones Anticipated in 2021--
Jan 4, 2021
- Safety Review Committee approved Phase 1b expansion cohorts in study arm evaluating zandelisib in combination with zanubrutinib in various B-cell maligniancies -
Nov 10, 2020
--Expands Clinical Development of Zandelisib to New Indications and Earlier Lines of Treatment--
Sep 9, 2020
- Strong cash position of ~$183 million at start of fiscal year 2021 -